Alnylam Pharma (ALNY): ASH Presentation Bodes Well For 2017 PhIII - Needham

Needham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) after the company presented updates from several clinical programs at ASH mtg this weekend, including initial fitusiran data in hemophilia pts w/ inhibitors, additional fitusiran data in hemophilia pts w/o inhibitors, and initial givosiran (ALN-AS1) data in porphyria pts w/ recurrent attacks.

The analyst noted an impressive zero annualized bleed rate was reported in patients w/ inhibitors. Based on disclosed biomarker and clinical data (no thrombotic events), he believes D-dimer elevations seen in some patients are not clinically meaningful. Longer-term data in patients w/o inhibitors also remains encouraging.

In the analyst's opinion, the overall fitusiran profile remains favorable and differentiated relative to current landscape. Phase 3 trials are expected to start 1H17.

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $41.57 yesterday.

You May Also Be Interested In

• Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
• Needham & Company reiterates Buy rating on Amazon (AMZN), raises estimates
• Needham Reiterates Buy Rating on Taiwan Semiconductor Manufacturing Co. Ltd. (TSM)